165 research outputs found
Optimisation of two-dimensional ion trap arrays for quantum simulation
The optimisation of two-dimensional (2D) lattice ion trap geometries for
trapped ion quantum simulation is investigated. The geometry is optimised for
the highest ratio of ion-ion interaction rate to decoherence rate. To calculate
the electric field of such array geometries a numerical simulation based on a
"Biot-Savart like law" method is used. In this article we will focus on square,
hexagonal and centre rectangular lattices for optimisation. A method for
maximising the homogeneity of trapping site properties over an array is
presented for arrays of a range of sizes. We show how both the polygon radii
and separations scale to optimise the ratio between the interaction and
decoherence rate. The optimal polygon radius and separation for a 2D lattice is
found to be a function of the ratio between rf voltage and drive frequency
applied to the array. We then provide a case study for 171Yb+ ions to show how
a two-dimensional quantum simulator array could be designed
Versatile ytterbium ion trap experiment for operation of scalable ion-trap chips with motional heating and transition-frequency measurements
We present the design and operation of an ytterbium ion trap experiment with a setup offering versatile optical access and 90 electrical interconnects that can host advanced surface and multilayer ion trap chips mounted on chip carriers. We operate a macroscopic ion trap compatible with this chip carrier design and characterize its performance, demonstrating secular frequencies >1 MHz, and trap and cool nearly all of the stable isotopes, including 171Yb+ ions, as well as ion crystals. For this particular trap we measure the motional heating rate 〈ṅ〉 and observe an 〈ṅ〉∝1/ω2 behavior for different secular frequencies ω. We also determine a spectral noise density SE(1 MHz)=3.6(9)×10-11 V2 m-2 Hz-1 at an ion electrode spacing of 310(10) μm. We describe the experimental setup for trapping and cooling Yb+ ions and provide frequency measurements of the 2S1/2↔2P1/2 and 2D3/2↔3D[3/2]1/2 transitions for the stable 170Yb+, 171Yb+, 172Yb+, 174Yb+, and 176Yb+ isotopes which are more precise than previously published work
Recommended from our members
Synthesis and functionalisation of superparamagnetic nano-rods towards the treatment of glioblastoma brain tumours
The complete removal of glioblastoma brain tumours is impossible to achieve by surgery alone due to the complex finger-like tentacle structure of the tumour cells and their migration away from the bulk of the tumour at the time of surgery; furthermore, despite aggressive chemotherapy and radiotherapy treatments following surgery, tumour cells continue to grow, leading to the death of patients within 15 months after diagnosis. The naturally occurring carnosine dipeptide has previously demonstrated activity against in vitro cultured glioblastoma cells; however, at natural physiological concentrations, its activity is too low to have a significant effect. Towards realising the full oncological potential of carnosine, the dipeptide was embedded within an externally triggered carrier, comprising a novel nano rod-shaped superparamagnetic iron oxide nanoparticle (ca. 86 × 19 × 11 nm) capped with a branched polyethyleneimine, which released the therapeutic agent in the presence of an external magnetic field. The new nano-carrier was characterized using electron microscopy, dynamic light scattering, elemental analysis, and magnetic resonance imaging techniques. In addition to cytotoxicity studies, the carnosine carrier’s effectiveness as a treatment for glioblastoma was screened in vitro using the U87 human glioblastoma astrocytoma cell line. The labile carnosine (100 mM) suppresses both the U87 cells’ proliferation and mobility over 48 h, resulting in significant reduction in migration and potential metastasis. Carnosine was found to be fully released from the carrier using only mild hyperthermia conditions (40 °C), facilitating an achievable clinical application of the slow, sustained-release treatment of glioblastoma brain tumours that demonstrates potential to inhibit post-surgery metastasis with the added benefit of non-invasive monitoring via MRI
Recommended from our members
Controlled release of carnosine from poly(lactic-co-glycolic acid) beads using nanomechanical magnetic trigger towards the treatment of glioblastoma
Nanometer scale rods of superparamagnetic iron oxide have been encapsulated, along with the anti-cancer therapeutic carnosine, inside porous poly(lactic-co-glycolic acid) microbeads with a uniform morphology, synthesised using microfluidic arrays. The sustained and externally triggered controlled release from these vehicles was demonstrated using a rotating Halbach magnet array, quantified via liquid chromatography, and imaged in situ using magnetic resonance imaging (MRI) and scanning electron microscopy (SEM). In the absence of the external magnetic trigger, the carnosine was found to be released from the polymer in a linear profile; however, over 50% of the drug could be released within 30 minutes of exposure to the rotating magnetic field. In addition, the release of carnosine embedded on the surface of the nano-rods was delayed if it was mixed with the iron oxide nano rods before the encapsulation. These new drug delivery vesicles have the potential to pave the way towards the safe and triggered release of onsite drug delivery, as part of a theragnostic treatment for glioblastoma
Importance of clinical and morphological correlations in diagnosing langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) is a clonal histiocytic disorder. The variable
clinical manifestations from isolated bone lesion to multisystem disease can cause
difficulties and delay in diagnosis. We report a 2 years and 8 months-old girl who
presented with a 2 weeks history of persistent fever and weight loss associated with
progressive abdominal distension. Physical examination revealed pallor, bilateral
proptosis, seaborrheic dermatitis over the scalp and hepatosplenomegaly. Skull
X-ray demonstrated multiple lytic lesions at the base and the skull vault. Bone
marrow morphology showed numerous abnormal Langerhans cells (LCs) and
foamy macrophages. The trephine immunohistochemistry (IHC) stains for CD1a,
S-100 and CD68 were inconclusive. The diagnosis of multisystem Langerhans
cell histiocytosis (MS-LCH) in this patient was based on the clinical presentation,
radiological and morphological analysis. She subsequently received chemotherapy
and currently she is on maintenance therapy with a good clinical response. LCH is
a rare disease and although the IHC was inconclusive, the correlation of clinical,
radiological and morphological data are essential for the diagnosis
Recommended from our members
Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments
Although the discovery and characterization of multiple tumor antigens have sparked the development of many antigen/derived cancer vaccines, many are poorly immunogenic and thus, lack clinical efficacy. Adjuvants are therefore incorporated into vaccine formulations to trigger strong and long-lasting immune responses. Adjuvants have generally been classified into two categories: those that ‘depot’ antigens (e.g. mineral salts such as aluminum hydroxide, emulsions, liposomes) and those that act as immunostimulants (Toll Like Receptor agonists, saponins, cytokines). In addition, several novel technologies using vector-based delivery of antigens have been used. Unfortunately, the immune system declines with age, a phenomenon known as immunosenescence, and this is characterized by functional changes in both innate and adaptive cellular immunity systems as well as in lymph node architecture. While many of the immune functions decline over time, others paradoxically increase. Indeed, aging is known to be associated with a low level of chronic inflammation—inflamm-aging. Given that the median age of cancer diagnosis is 66 years and that immunotherapeutic interventions such as cancer vaccines are currently given in combination with or after other forms of treatments which themselves have immune-modulating potential such as surgery, chemotherapy and radiotherapy, the choice of adjuvants requires careful consideration in order to achieve the maximum immune response in a compromised environment. In addition, more clinical trials need to be performed to carefully assess how less conventional form of immune adjuvants, such as exercise, diet and psychological care which have all be shown to influence immune responses can be incorporated to improve the efficacy of cancer vaccines. In this review, adjuvants will be discussed with respect to the above-mentioned important elements
First detection of a VHE gamma-ray spectral maximum from a Cosmic source: H.E.S.S. discovery of the Vela X nebula
The Vela supernova remnant (SNR) is a complex region containing a number of
sources of non-thermal radiation. The inner section of this SNR, within 2
degrees of the pulsar PSR B0833-45, has been observed by the H.E.S.S. gamma-ray
atmospheric Cherenkov detector in 2004 and 2005. A strong signal is seen from
an extended region to the south of the pulsar, within an integration region of
radius 0.8 deg. around the position (RA = 08h 35m 00s, dec = -45 deg. 36'
J2000.0). The excess coincides with a region of hard X-ray emission seen by the
ROSAT and ASCA satellites. The observed energy spectrum of the source between
550 GeV and 65 TeV is well fit by a power law function with photon index = 1.45
+/- 0.09(stat) +/- 0.2(sys) and an exponential cutoff at an energy of 13.8 +/-
2.3(stat) +/- 4.1(sys) TeV. The integral flux above 1 TeV is (1.28 +/- 0.17
(stat) +/- 0.38(sys)) x 10^{-11} cm^{-2} s^{-1}. This result is the first clear
measurement of a peak in the spectral energy distribution from a VHE gamma-ray
source, likely related to inverse Compton emission. A fit of an Inverse Compton
model to the H.E.S.S. spectral energy distribution gives a total energy in
non-thermal electrons of ~2 x 10^{45} erg between 5 TeV and 100 TeV, assuming a
distance of 290 parsec to the pulsar. The best fit electron power law index is
2.0, with a spectral break at 67 TeV.Comment: 5 pages, 4 figures, accepted for publication in Astronomy and
Astrophysics letter
Rumours, sects and rallies : the ethnic politics of recent Hmong Millenarian movements in Vietnam’s highlands
Contrary to modernist assumptions, millenarianism has not died out but continues to influence the politics of many marginalised groups in upland Southeast Asia, including the Hmong. This article summarises and analyses post-World War II Hmong millenarian activity in Vietnam, focusing on three case studies from the 1980s onwards, within the political backdrop of ongoing government suspicions of ethnic separatism and foreign interference. Far from being isolated or peripheral, Hmong millenarian rumours and movements interact with overseas diasporas, human rights agencies and international religious networks to influence state responses, sometimes in unexpected ways
3.9 day orbital modulation in the TeV gamma-ray flux and spectrum from the X-ray binary LS 5039
New observations of LS 5039, a High Mass X-ray Binary comprising a massive
star and compact object, were carried out with the High Energy Stereoscopic
System of Cherenkov Telescopes (H.E.S.S.) in 2005 at very high energy (VHE)
gamma-ray energies. These observations reveal that its flux and energy spectrum
are modulated with the 3.9 day orbital period of the binary system. This is the
first time in gamma-ray astronomy that orbital modulation has been observed,
and periodicity clearly established using ground-based gamma-ray detectors. The
VHE gamma-ray emission is largely confined to half of the orbit, peaking around
the inferior conjunction epoch of the compact object. For this epoch, there is
also a hardening of the energy spectrum in the energy range between 0.2 TeV and
a few TeV. The flux vs. orbital phase profile provides the first clear
indication of gamma-ray absorption via pair production within an astrophysical
source, a process which is expected to occur if the gamma-ray production site
is situated within ~1 AU of the compact object. Moreover the production region
size must be not significantly greater than the binary separation (~0.15 AU).
Notably, these constraints are also considerably smaller than the collimated
outflows or jets (extending out to ~1000 AU) observed in LS 5039. The spectral
hardening could arise from variations with phase in the maximum electron
energies, and/or the dominant VHE gamma-ray production mechanism.Comment: 8 pages, 8 figures, accepted for publication in Astronomy &
Astrophysic
Duffy blood group gene polymorphisms among malaria vivax patients in four areas of the Brazilian Amazon region
<p>Abstract</p> <p>Background</p> <p>Duffy blood group polymorphisms are important in areas where <it>Plasmodium vivax </it>predominates, because this molecule acts as a receptor for this protozoan. In the present study, Duffy blood group genotyping in <it>P. vivax </it>malaria patients from four different Brazilian endemic areas is reported, exploring significant associations between blood group variants and susceptibility or resistance to malaria.</p> <p>Methods</p> <p>The <it>P. vivax </it>identification was determined by non-genotypic and genotypic screening tests. The Duffy blood group was genotyped by PCR/RFLP in 330 blood donors and 312 malaria patients from four Brazilian Amazon areas. In order to assess the variables significance and to obtain independence among the proportions, the Fisher's exact test was used.</p> <p>Results</p> <p>The data show a high frequency of the <it>FYA/FYB </it>genotype, followed by <it>FYB/FYB, FYA/FYA</it>, <it>FYA/FYB-33 </it>and <it>FYB/FYB-33</it>. Low frequencies were detected for the <it>FYA/FY</it><sup><it>X</it></sup>, <it>FYB/FY</it><sup><it>X</it></sup>, <it>FYX/FY</it><sup><it>X </it></sup>and <it>FYB-33/FYB-33 </it>genotypes. Negative Duffy genotype (<it>FYB-33/FYB-33</it>) was found in both groups: individuals infected and non-infected (blood donors). No individual carried the <it>FY</it><sup><it>X</it></sup><it>/FYB-33 </it>genotype. Some of the Duffy genotypes frequencies showed significant differences between donors and malaria patients.</p> <p>Conclusion</p> <p>The obtained data suggest that individuals with the <it>FYA/FYB </it>genotype have higher susceptibility to malaria. The presence of the <it>FYB-33 </it>allele may be a selective advantage in the population, reducing the rate of infection by <it>P. vivax </it>in this region. Additional efforts may contribute to better elucidate the physiopathologic differences in this parasite/host relationship in regions endemic for <it>P. vivax </it>malaria, in particular the Brazilian Amazon region.</p
- …